Changes in Hong Kong stocks | CSPC Group (01093) rose more than 4% to obtain top-line analysis data for the phase III clinical trial of scuchiyumab injection

The Zhitong Finance App learned that CSPC Group (01093) rose by more than 4%. As of press release, it had risen 4.37% to HK$8.36, with a turnover of HK$579 million.

According to the news, on December 18, Shiyao Group announced that the scuchiumab injection (this product) developed by Shiyao Group Jushi Biopharmaceutical Co., Ltd., a subsidiary of the company, obtained top-line analysis data in an equivalent phase III clinical trial for the treatment of moderate to severe plaque psoriasis.

^{This product is an all-human IgG1 monoclonal antibody drug developed by the Group and is a biosimilar to scuchiumab injection (Kesanting®).} The approved indications for Kesanting ^® in China include plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa in the age of 6 and above, and its efficacy and safety have been widely recognized.

The key study has reached its intended primary endpoint and achieved positive top-line results. Statistical analysis shows that this product is clinically equivalent to Kesanting ^® and has good safety. There are no new or unexpected safety signals, and it is expected to meet the safety requirements of patients for long-term medication use. Detailed data on the study will be published in subsequent academic conferences and journals.